PROOF Centre Collaboration Focuses on Prognostic Biomarkers for Chronic Kidney Disease
Today the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) announced a new partnership with AstraZeneca and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) to develop a blood test to predict the rate of disease progression in patients with chronic kidney disease (CKD).
For the discovery phase of the project, PROOF Centre and AstraZeneca researchers will leverage the large cohort and rich clinical data available from the CanPREDDICT study. The collective team of clinical, computational, technical and biological experts will use the PROOF Centre's computationally-driven omics biomarker development pipeline to identify genomic and proteomic biomarkers that can discriminate patients who have rapid versus slow CKD progression. The PROOF Centre will support the analysis process from front-end experimental design to downstream statistical and biological analysis.
“Biomarkers to better predict disease progression will be a valuable tool to provide more personalized care for patients suffering from CKD. If developed as a blood test that corresponds to different patient trajectories, it will offer clinicians a better way of knowing which patients need more intensive medical attention and management,” says CanPREDDICT lead investigator and Head of UBC Division of Nephrology, Dr. Adeera Levin.
Ken, cardiac patient